Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pyxis Oncology (PYXS) Income from Continuing Operations (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Income from Continuing Operations for 2 consecutive years, with 23219000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations fell 22.31% to 23219000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 100739000.0, a N/A change, with the full-year FY2024 number at 77331000.0, down 4.66% from a year prior.
  • Income from Continuing Operations was 23219000.0 for Q3 2025 at Pyxis Oncology, down from 18071000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 5343000.0 in Q1 2024 to a low of 37735000.0 in Q4 2024.